Literature DB >> 6596587

Dexamethasone suppression test (DST) and plasma dexamethasone levels in depressed patients.

G F Johnson, G Hunt, K Kerr, I Caterson.   

Abstract

The dexamethasone suppression test (DST) was evaluated in newly hospitalized patients with a DSM-III diagnosis of major depression. Patients with other psychiatric disorders and a normal control group were also studied. Plasma dexamethasone levels were obtained in all patients, and the relationship between plasma cortisol and plasma dexamethasone was examined. Rates of non-suppression in patients with major depression (39%) were not significantly different from those in patients with minor depression (25%), mania (38%), or other psychiatric illnesses (17%). The ranges of dexamethasone levels at 8 a.m. and 4 p.m. were similar between patient groups and controls. However, there was a significant difference in dexamethasone levels between suppressors and nonsuppressors, irrespective of diagnosis, which could not be explained by differences in weight or plasma dexamethasone half-life. Inappropriately high dexamethasone levels were found in some patients with a 1 mg test, a problem that critically affects the sensitivity of the test procedure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6596587     DOI: 10.1016/0165-1781(84)90078-7

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

1.  Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patients.

Authors:  S K Gupta; J C Ritchie; E H Ellinwood; K Wiedemann; F Holsboer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacoendocrinology of major depression.

Authors:  R T Rubin
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

3.  Judgement of the hypothalamic-pituitary-adrenocortical function in psychiatric patients by betamethasone-induced cortisol suppressibility.

Authors:  S Kasper; P Vecsei; P Richter; D Haack; K Diebold; L Katzinski
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.